MTFR2 and neoplasm: Subgroup survival analyses revealed elevated MTFR2 expression correlated worse survival with clinical features including T3 stage, N0 stage, M0 stage, female, smoker, >65 years, residual R0 tumor, and pathologic stage (Figures 3E–L).